DELOS Nanovesicles-Based Hydrogels: An Advanced Formulation for Topical Use.
Lídia Ballell-Hosa1,2,3, Elisabet González-Mira2,3, Hector Santana4
1Nanomol Technologies S.L., 08193 Cerdanyola del Vallès, Spain.
Pharmaceutics
|January 21, 2022
Summary
DELOS nanovesicles were successfully formulated into stable hydrogels for enhanced topical drug delivery. This advanced formulation maintains nanocarrier integrity and improves the bioactivity of encapsulated therapeutics like recombinant human Epidermal Growth Factor (rhEGF).
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Dermatology
Background:
- Topical drug delivery offers localized treatment with improved patient compliance and reduced side effects.
- Current topical treatments face challenges that innovative drug delivery systems aim to address.
- DELOS nanovesicles have shown potential for topical complex wound treatment.
Purpose of the Study:
- To develop DELOS nanovesicles with optimal skin tolerability for application on damaged skin.
- To adapt DELOS nanovesicle dispersions into a suitable topical hydrogel formulation.
- To confirm nanocarrier integrity post-gellification and evaluate the bioactivity of encapsulated rhEGF.
Main Methods:
- Formulation of DELOS nanovesicles into hydrogels using Methocel™ K4M.
- Characterization of hydrogel stability and rheological properties.
- Confirmation of nanocarrier integrity via cryo-transmission electron microscopy and Förster resonance energy transfer analysis.
- In vitro assessment of rhEGF bioactivity in gellified versus liquid nanovesicles.
Main Results:
- DELOS nanovesicles were successfully incorporated into stable hydrogels with appropriate rheological properties.
- Nanocarrier integrity was confirmed after hydrogel formation, a critical but rarely reported finding.
- Recombinant human Epidermal Growth Factor (rhEGF) within the hydrogel formulation showed enhanced bioactivity compared to the liquid form.
Conclusions:
- DELOS nanovesicles can be effectively formulated into hydrogels without compromising their integrity.
- DELOS nanovesicles-based hydrogels represent an advanced topical drug delivery system.
- This formulation enhances the bioactivity of encapsulated therapeutic proteins for topical applications.
Related Concept Videos
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...